| ||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||
| Copyright © 2009. National Academy of Sciences. All rights reserved. Terms of Use and Privacy Statement |
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 75
Page 75
APPENDIX B
March 8, 2001 Meeting Agenda
IMMUNIZATION SAFETY REVIEW COMMITTEE MEASLES-MUMPS-RUBELLA VACCINE AND AUTISM MEETING
National Academies Building
2101 Constitution Ave., NW
Washington, D.C.
SESSION I: ETIOLOGY, DIAGNOSIS, AND EPIDEMIOLOGY OF AUTISM
8:30–8:35 a.m.
Opening Remarks
Marie McCormick, M.D., Sc.D., Chair, Immunization Safety Review Committee
8:35–9:00 a.m.
Neurobiology and Neuropathology of Autism
Thomas Kemper, M.D., Professor, Department of Neurology, Anatomy, and Pathology, Boston University School of Medicine
9:00–9:30 a.m.
Etiology of Autism and NIH Research
Marie Bristol-Power, Ph.D., Special Assistant on Autism, Office of the Director, National Institute of Child Health and Human Development, National Institutes of Health
OCR for page 76
Page 76
9:30–10:00 a.m.
Diagnosis and Assessment of Autism
Fred Volkmar, M.D., Professor of Child Psychiatry, Pediatrics, and Psychology, Yale Child Study Center
10:15–10:45 a.m.
Epidemiological Evidence on Rates of Autism and Time Trends
Eric Fombonne, M.D., FRCPsych, Reader in Epidemiological Child Psychiatry, Institute of Psychiatry, King's College London
10:45–11:00 a.m.
Trends in Students with Autism in IDEA Programs
Louis Danielson, Ph.D., Director of Research to Practice Division, Office of Special Education Programs, Department of Education
11:00–11:45 a.m.
Discussion Panel
Kathryn Carbone, M.D., Chief, Laboratory of Pediatric and Respiratory Viral Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration
Karin Nelson, M.D., Senior Investigator, Neuroepidemiology Branch, National Institute for Neurological Disorders and Stroke, National Institutes of Health
Ezra Susser, M.D., Head, Division of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University
SESSION II: MMR AND AUTISM HYPOTHESIS
12:30–1:30 p.m.
Hypothesis and Data Linking MMR, Bowel Symptoms and Autism
Andrew Wakefield, M.D., Royal Free & University College Medical School, United Kingdom
Kenneth Aitken, Ph.D., Independent Consultant Child Clinical Neuropsychologist
1:30–2:00 p.m.
Overview of Epidemiological Studies Examining Potential Link Between MMR, Bowel Symptoms, and Autism
Michael Stoto, Ph.D., Chair, Department of Epidemiology and Biostatistics, George Washington University
2:00–2:30 p.m.
New Data and Research Findings Regarding a Potential Link Between MMR, Bowel Symptoms, and Autism
OCR for page 77
Page 77
Eric Fombonne, M.D., FRCPsych, Reader in Epidemiological Child Psychiatry, Institute of Psychiatry, King's College London
2:45–4:00 p.m.
Discussion Panel
Scott Montgomery, Ph.D., Karolinska Institute, Sweden
Brian Ward, M.D., Associate Professor, Medicine & Microbiology, McGill University and Montreal General Hospital Research Institute
Michael Gershon, M.D., Professor and Chair, Department of Anatomy and Cell Biology, Columbia University
Kathryn Carbone, M.D., Chief, Laboratory of Pediatric and Respiratory Viral Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration
Karin Nelson, M.D., Senior Investigator, Neuroepidemiology Branch, National Institute for Neurological Disorders and Stroke, National Institutes of Health
4:00–4:15 p.m.
Study of Autism and the Vaccine Adverse Event Reporting System (VAERS)
Jane Woo, M.D., M.P.H., Fellow, Vaccine Safety Branch, Division of Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration
4:15–5:00 p.m.
Public Comment Session
OCR for page 78
Page 78
Representative terms from entire chapter:
child psychiatry